Researchers at the UConn Center on Aging have uncovered causal links between depression and Alzheimer’s disease and related ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Dr. Ausim Azizi is among those seeing the overall early results, as Yale New Haven Hospital is in the forefront of research ...

Let’s keep it simple: If you want to delay Alzheimer’s onset, focus on walking and adding nutritious foods, such as walnuts, ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

The idea that herpes infections trigger or contribute to Alzheimer's disease has been gaining favor among some scientists, ...

The Alzheimer’s Association has issued its first clinical practice guideline on the use of blood tests to help diagnose ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

TORONTO -- Blood tests for Alzheimer's disease biomarkers can be used clinically -- and can replace expensive brain scans and ...

New tests and new treatments are presenting more options for certain patients with Alzheimer's disease. “Today a confluence ...

Alzheimer's disease (AD) is a progressive neurocognitive disease that slowly erodes an individual's memory, judgment, cognition, learning, and, eventually, ability to function. It is the leading ...